Neuroprotective actions of estradiol revisited

Trends in Endocrinology and Metabolism

Volumn 22, Issue 12, 2011, Pages 467-473

  Azcoitia, Iñigo ^a   Arevalo, Maria Angeles ^b   De Nicola, Alejandro F ^c   Garcia Segura, Luis M ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b INSTITUTO CAJAL   (Spain)

^c INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CONJUGATED ESTROGEN; CONTRACEPTIVE AGENT; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NEUROGLOBIN; PROGESTERONE; SELADIN 1; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; WNT PROTEIN;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BRAIN FUNCTION; BRAIN ISCHEMIA; BRAIN MITOCHONDRION; BRAIN NERVE CELL; CANCER RISK; CENTRAL NERVOUS SYSTEM; COGNITION; CYTOPLASM; DEMENTIA; DEMYELINATING DISEASE; ENDOMETRIUM CANCER; ESTROGEN ACTIVITY; ESTROGEN SYNTHESIS; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; HYPERTENSION; MITOCHONDRIAL GENOME; MULTIPLE SCLEROSIS; NERVE CELL MEMBRANE; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE; STROKE; TRAUMATIC BRAIN INJURY;

AGING; ANIMALS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MALE; NEUROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES;

EID: 82555167020     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2011.08.002     Document Type: Review

References (72)

1. Shumaker S.A., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study. J. Am. Med. Assoc. 2003, 289:2651-2662.
2. Pike C.J., et al. Protective actions of sex steroid hormones in Alzheimer's disease. Front. Neuroendocrinol. 2009, 30:239-258.
3. Bourque M., et al. Neuroprotective actions of sex steroids in Parkinson's disease. Front. Neuroendocrinol. 2009, 30:142-157.
4. Suzuki S., et al. Neuroprotective effects of estrogens following ischemic stroke. Front. Neuroendocrinol. 2009, 30:201-211.
5. Etgen A.M., et al. Neuroprotective actions of estradiol and novel estrogen analogs in ischemia: Translational implications. Front. Neuroendocrinol. 2011, 32:336-352.
6. Kipp M., Beyer C. Impact of sex steroids on neuroinflammatory processes and experimental multiple sclerosis. Front. Neuroendocrinol. 2009, 30:188-200.
7. Pietranera L., et al. Involvement of brain-derived neurotrophic factor and neurogenesis in oestradiol neuroprotection of the hippocampus of hypertensive rats. J. Neuroendocrinol. 2010, 22:1082-1092.
8. Barreto G., et al. Selective estrogen receptor modulators decrease astrogliosis in the injured brain: effects of aging and prolonged depletion of ovarian hormones. Endocrinology 2009, 150:5010-5015.
9. Saraceno G.E., et al. Estradiol therapy in adulthood reverses glial and neuronal alterations caused by perinatal asphyxia. Exp. Neurol. 2010, 223:615-622.
10. Tiwari-Woodruff S., Voskuhl R.R. Neuroprotective and anti-inflammatory effects of estrogen receptor ligand treatment in mice. J. Neurol. Sci. 2009, 286:81-85.
11. Jover-Mengual T., et al. MAPK signaling is critical to estradiol protection of CA1 neurons in global ischemia. Endocrinology 2007, 148:1131-1143.
12. Yang L.C., et al. Extranuclear estrogen receptors mediate the neuroprotective effects of estrogen in the rat hippocampus. PLoS ONE 2010, 5:e9851.
13. Gingerich S., et al. Estrogen receptor alpha and G-protein coupled receptor 30 mediate the neuroprotective effects of 17beta-estradiol in novel murine hippocampal cell models. Neuroscience 2010, 170:54-66.
14. Lebesgue D., et al. Acute administration of non-classical estrogen receptor agonists attenuates ischemia-induced hippocampal neuron loss in middle-aged female rats. PLoS ONE 2010, 5:e8642.
15. Ruiz-Palmero I., et al. Notch/Neurogenin 3 signalling is involved in the neuritogenic actions of oestradiol in developing hippocampal neurones. J. Neuroendocrinol. 2011, 23:355-364.
16. Gorosito S.V., et al. Estrogen receptor alpha is expressed on the cell-surface of embryonic hypothalamic neurons. Neuroscience 2008, 154:1173-1177.
17. Dominguez R., Micevych P. Estradiol rapidly regulates membrane estrogen receptor alpha levels in hypothalamic neurons. J. Neurosci. 2010, 30:12589-12596.
18. Marin R., et al. Role of estrogen receptor alpha in membrane-initiated signaling in neural cells: interaction with IGF-1 receptor. J. Steroid Biochem. Mol. Biol. 2009, 114:2-7.
19. Herrera J.L., et al. Estradiol and tamoxifen differentially regulate a plasmalemmal voltage-dependent anion channel involved in amyloid-beta induced neurotoxicity. Steroids 2011, 76:840-844.
20. Ramírez C.M., et al. VDAC and ERalpha interaction in caveolae from human cortex is altered in Alzheimer's disease. Mol. Cell. Neurosci. 2009, 42:172-183.
21. Garcia-Segura L.M., et al. Interactions of estradiol and insulin-like growth factor-I signalling in the nervous system: new advances. Prog. Brain Res. 2010, 181:251-272.
22. Alonso A., et al. Chronic estradiol treatment improves brain homeostasis during aging in female rats. Endocrinology 2008, 149:57-72.
23. Varea O., et al. Interaction of estrogen receptors with insulin-like growth factor-I and Wnt signaling in the nervous system. Steroids 2010, 75:565-569.
24. Selvamani A., Sohrabji F. The neurotoxic effects of estrogen on ischemic stroke in older female rats is associated with age-dependent loss of insulin-like growth factor-1. J. Neurosci. 2010, 30:6852-6861.
25. Quesada A., et al. PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease. Dev. Neurobiol. 2008, 68:632-644.
26. Lebesgue D., et al. Estradiol rescues neurons from global ischemia-induced cell death: multiple cellular pathways of neuroprotection. Steroids 2009, 74:555-561.
27. Zhang Q.G., et al. Role of Dickkopf-1, an antagonist of the Wnt/beta-catenin signaling pathway, in estrogen-induced neuroprotection and attenuation of tau phosphorylation. J. Neurosci. 2008, 28:8430-8441.
28. Peri A., et al. New insights on the neuroprotective role of sterols and sex steroids: the seladin-1/DHCR24 paradigm. Front. Neuroendocrinol. 2009, 30:119-129.
29. 2-induced toxicity. Neurosignals 2011, 18:223-235.
30. Simpkins J.W., et al. Mitochondrial mechanisms of estrogen neuroprotection. Biochim. Biophys. Acta 2010, 1800:1113-1120.
31. Arevalo M.A., et al. Actions of estrogens on glial cells: implications for neuroprotection. Biochim. Biophys. Acta 2010, 1800:1106-1112.
32. Taylor L.C., et al. 17beta-Estradiol protects male mice from cuprizone-induced demyelination and oligodendrocyte loss. Neurobiol. Dis. 2010, 39:127-137.
33. Carbonaro V., et al. Enhanced expression of ERalpha in astrocytes modifies the response of cortical neurons to beta-amyloid toxicity. Neurobiol. Dis. 2009, 33:415-421.
34. Azcoitia I., et al. Role of astroglia in the neuroplastic and neuroprotective actions of estradiol. Eur. J. Neurosci. 2010, 32:1995-2002.
35. Giraud S.N., et al. Estradiol inhibits ongoing autoimmune neuroinflammation and NFkappaB-dependent CCL2 expression in reactive astrocytes. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:8416-8421.
36. Spence R.D., et al. Neuroprotection mediated through estrogen receptor α in astrocytes. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:8867-8872.
37. López Rodríguez A.B., et al. Estradiol decreases cortical reactive astrogliosis after brain injury by a mechanism involving cannabinoid receptors. Cereb. Cortex 2011, 21:2046-2055.
38. Crawford D.K., et al. Oestrogen receptor beta ligand: a novel treatment to enhance endogenous functional remyelination. Brain 2010, 133:2999-3016.
39. Du S., et al. Estrogen receptor-β ligand treatment modulates dendritic cells in the target organ during autoimmune demyelinating disease. Eur. J. Immunol. 2011, 41:140-150.
40. Hirahara Y., et al. The localization and non-genomic function of the membrane-associated estrogen receptor in oligodendrocytes. Glia 2009, 57:153-165.
41. Azcoitia I., et al. Estradiol synthesis within the human brain. Neuroscience 2011, 191:139-147.
42. Remage-Healey L., et al. Brain estrogens rapidly strengthen auditory encoding and guide song preference in a songbird. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:3852-3857.
43. Zhou L., et al. Aromatase inhibitors induce spine synapse loss in the hippocampus of ovariectomized mice. Endocrinology 2010, 151:1153-1160.
44. Charlier T.D., et al. Diversity of mechanisms involved in aromatase regulation and estrogen action in the brain. Biochim. Biophys. Acta 2010, 1800:1094-1105.
45. Gatson J.W., et al. Aromatase is increased in astrocytes in the presence of elevated pressure. Endocrinology 2011, 152:207-213.
46. Saldanha C.J., et al. Neuroprotective actions of brain aromatase. Front. Neuroendocrinol. 2009, 30:106-118.
47. Garcia-Segura L.M. Aromatase in the brain: not just for reproduction anymore. J. Neuroendocrinol. 2008, 20:705-712.
48. Pietranera L., et al. Increased aromatase expression in the hippocampus of spontaneously hypertensive rats: effects of estradiol administration. Neuroscience 2011, 174:151-159.
49. De Nicola A.F. Progesterone neuroprotection in traumatic CNS injury and motoneuron degeneration. Front. Neuroendocrinol. 2009, 30:173-187.
50. Stein D.G., Wright D.W. Progesterone in the clinical treatment of acute traumatic brain injury. Expert. Opin. Invest. Drugs 2010, 19:847-857.
51. Frye C.A., Walf A. Progesterone, administered before kainic acid, prevents decrements in cognitive performance in the Morris Water Maze. Dev. Neurobiol. 2011, 71:142-152.
52. Moralí G., et al. Neuroprotective effects of progesterone and allopregnanolone on long-term cognitive outcome after global cerebral ischemia. Restor. Neurol. Neurosci. 2011, 29:1-15.
53. Ciriza I., et al. Reduced metabolites mediate neuroprotective effects of progesterone in the adult rat hippocampus. The synthetic progestin medroxyprogesterone acetate (Provera) is not neuroprotective. J. Neurobiol. 2006, 66:916-928.
54. Irwin R.W., et al. Medroxyprogesterone acetate antagonizes estrogen up-regulation of brain mitochondrial function. Endocrinology 2011, 152:556-567.
55. Morissette M., et al. Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Mol. Cell. Endocrinol. 2008, 290:60-69.
56. Acs P., et al. 17beta-Estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice. Glia 2009, 57:807-814.
57. Dang J., et al. Gonadal steroids prevent cell damage and stimulate behavioral recovery after transient middle cerebral artery occlusion in male and female rats. Brain Behav. Immun. 2011, 25:715-726.
58. Lima F.B., Bethea C.L. Ovarian steroids decrease DNA fragmentation in the serotonin neurons of non-injured rhesus macaques. Mol. Psychiatry 2010, 15:657-668.
59. Carroll J.C., et al. Continuous and cyclic progesterone differentially interact with estradiol in the regulation of Alzheimer-like pathology in female 3× transgenic-Alzheimer's disease mice. Endocrinology 2010, 151:2713-2722.
60. Maki P.M., et al. Perimenopausal use of hormone therapy is associated with enhanced memory and hippocampal function later in life. Brain Res. 2011, 1379:232-243.
61. Rocca W.A., et al. Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity. Brain Res. 2011, 1379:188-198.
62. Hogervorst E., Bandelow S. Sex steroids to maintain cognitive function in women after the menopause: a meta-analyses of treatment trials. Maturitas 2010, 66:56-71.
63. Suzuki S., et al. Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:6013-6018.
64. Hamilton R.T., et al. Hippocampal responsiveness to 17β-estradiol and equol after long-term ovariectomy: Implication for a therapeutic window of opportunity. Brain Res. 2011, 1379:11-22.
65. Selvamani A., Sohrabji F. Reproductive age modulates the impact of focal ischemia on the forebrain as well as the effects of estrogen treatment in female rats. Neurobiol. Aging 2010, 31:1618-1628.
66. Strom J.O., et al. Different methods for administering 17beta-estradiol to ovariectomized rats result in opposite effects on ischemic brain damage. BMC Neurosci. 2010, 11:39.
67. Arevalo M.A., et al. Selective estrogen receptor modulators as brain therapeutic agents. J. Mol. Endocrinol. 2011, 46:R1-R9.
68. Lagunas N., et al. Estrogen receptor ligands counteract cognitive deficits caused by androgen deprivation in male rats. Horm. Behav. 2011, 59:581-584.
69. Walf A.A., Frye C.A. Raloxifene and/or estradiol decrease anxiety-like and depressive-like behavior, whereas only estradiol increases carcinogen-induced tumorigenesis and uterine proliferation among ovariectomized rats. Behav. Pharmacol. 2010, 21:231-240.
70. Espeland M.A., et al. Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. J. Womens Health (Larchmt.) 2010, 19:371-379.
71. Picazo O., et al. Neuroprotective actions of the synthetic estrogen 17alpha-ethynylestradiol in the hippocampus. Cell. Mol. Neurobiol. 2010, 30:675-682.
72. Yi K.D., et al. The assessment of non-feminizing estrogens for use in neuroprotection. Brain Res. 2011, 1379:61-70.